Omniscient Neurotechnology vs Genentech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Omniscient Neurotechnology (o8t) is the pioneer of clinical connectomics with its FDA-cleared Quicktome brain mapping platform; raised up to $36M Series D led by NRFC ($20M); partnered with Jacobs Institute in 2025.
About
Omniscient Neurotechnology (branded as o8t) is an Australian medical technology company founded in 2019 and headquartered in Sydney. Omniscient is the global pioneer of clinical connectomics — the application of brain network science to patient care. Its flagship product, Quicktome, is the world''s first FDA-cleared medical device to generate detailed maps of brain networks from standard MRI scans using artificial intelligence and machine learning. Neurosurgeons use Quicktome before life-changing brain surgeries to visualize critical functional networks (motor, language, vision, memory) and plan surgical approaches that minimize neurological damage.
Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.
About
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Omniscient Neurotechnology vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.